KLI

p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations

Metadata Downloads
Abstract
Background: TP53 is the most frequently mutated gene in the human cancer, and the awareness of its mutational status is useful in the diagnosis and treatment of cancer patients. In the present study, we investigated the association between TP53 gene mutations and p53 immunohistochemical staining (IHC) patterns and non-genetic effect of MDM2 as a negative regulator of p53.

Methods: A total of 135 solid cancer cases with next generation sequencing data were subjected to p53 IHC and classified as overexpression, null type or usual pattern.

Results: TP53 mutation was observed in 104 out of 135 cases (77.0%). When the TP53 mutations were annotated into DISRUPTED (truncations, frameshifts, splice site mutations, and deep deletions) and IF-DBD (in-frame mutations in the DNA binding domain), the null type p53 IHC pattern was associated with DISRUPTED mutations (sensitivity 86.2%, specificity 97.2%) while the overexpression pattern was associated with IF-DBD mutations (sensitivity 100%, specificity 81.7%). The specificity of p53 IHC usual pattern predicting wild type TP53 was also as high as 100%. Regardless of MDM2 amplification, p53 IHC pattern showed a perfect association with TP53 mutation pattern.

Conclusions: p53 IHC pattern (overexpression, null type, usual) reasonably predicted TP53 mutational status (DISRUPTED, IF-DBD), and MDM2 amplification status did not have any impact on the p53 IHC pattern.
Author(s)
You-Na SungDeokhoon KimJihun Kim
Issued Date
2022
Type
Article
Keyword
AssociationImmunohistochemistryMutationTP53 genep53 protein
DOI
10.1186/s13000-022-01273-w
URI
https://oak.ulsan.ac.kr/handle/2021.oak/14870
Publisher
Diagnostic Pathology
Language
한국어
ISSN
1746-1596
Citation Volume
17
Citation Number
1
Citation Start Page
92
Citation End Page
101
Appears in Collections:
Medicine > Nursing
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.